216 related articles for article (PubMed ID: 32646968)
1. Epigenetic CRISPR Screens Identify
Li F; Ng WL; Luster TA; Hu H; Sviderskiy VO; Dowling CM; Hollinshead KER; Zouitine P; Zhang H; Huang Q; Ranieri M; Wang W; Fang Z; Chen T; Deng J; Zhao K; So HC; Khodadadi-Jamayran A; Xu M; Karatza A; Pyon V; Li S; Pan Y; Labbe K; Almonte C; Poirier JT; Miller G; Possemato R; Qi J; Wong KK
Cancer Res; 2020 Sep; 80(17):3556-3567. PubMed ID: 32646968
[TBL] [Abstract][Full Text] [Related]
2. Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression.
Zang X; Gu J; Zhang J; Shi H; Hou S; Xu X; Chen Y; Zhang Y; Mao F; Qian H; Zhu T; Xu W; Zhang X
Cell Death Dis; 2020 Apr; 11(4):215. PubMed ID: 32242003
[TBL] [Abstract][Full Text] [Related]
3. Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1α and APC2 gene expression in non-small cell lung cancer.
Zhang K; Wang J; Yang L; Yuan YC; Tong TR; Wu J; Yun X; Bonner M; Pangeni R; Liu Z; Yuchi T; Kim JY; Raz DJ
Mol Cancer; 2018 Oct; 17(1):153. PubMed ID: 30348169
[TBL] [Abstract][Full Text] [Related]
4. Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits.
Wu Z; Liu Z; Jiang X; Mi Z; Meng M; Wang H; Zhao J; Zheng B; Yuan Z
J Exp Clin Cancer Res; 2019 Aug; 38(1):341. PubMed ID: 31387622
[TBL] [Abstract][Full Text] [Related]
5. Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor.
Kuo KT; Huang WC; Bamodu OA; Lee WH; Wang CH; Hsiao M; Wang LS; Yeh CT
Clin Epigenetics; 2018 Aug; 10(1):107. PubMed ID: 30092824
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis.
Hua Q; Mi B; Xu F; Wen J; Zhao L; Liu J; Huang G
Theranostics; 2020; 10(11):4762-4778. PubMed ID: 32308748
[No Abstract] [Full Text] [Related]
7. Targeting NPM1 in irradiated cells inhibits NPM1 binding to RAD51, RAD51 foci formation and radiosensitizes NSCLC.
Traver G; Sekhar KR; Crooks PA; Keeney DS; Freeman ML
Cancer Lett; 2021 Mar; 500():220-227. PubMed ID: 33358698
[TBL] [Abstract][Full Text] [Related]
8. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling.
Wagner KW; Alam H; Dhar SS; Giri U; Li N; Wei Y; Giri D; Cascone T; Kim JH; Ye Y; Multani AS; Chan CH; Erez B; Saigal B; Chung J; Lin HK; Wu X; Hung MC; Heymach JV; Lee MG
J Clin Invest; 2013 Dec; 123(12):5231-46. PubMed ID: 24200691
[TBL] [Abstract][Full Text] [Related]
9. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
Garmendia I; Pajares MJ; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba II; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga LM; Agorreta J
Am J Respir Crit Care Med; 2019 Oct; 200(7):888-899. PubMed ID: 31166114
[No Abstract] [Full Text] [Related]
10. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer.
Burns TF; Dobromilskaya I; Murphy SC; Gajula RP; Thiyagarajan S; Chatley SN; Aziz K; Cho YJ; Tran PT; Rudin CM
Mol Cancer Res; 2013 Apr; 11(4):329-38. PubMed ID: 23364532
[TBL] [Abstract][Full Text] [Related]
12. In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis.
Wu Q; Tian Y; Zhang J; Tong X; Huang H; Li S; Zhao H; Tang Y; Yuan C; Wang K; Fang Z; Gao L; Hu X; Li F; Qin Z; Yao S; Chen T; Chen H; Zhang G; Liu W; Sun Y; Chen L; Wong KK; Ge K; Chen L; Ji H
Proc Natl Acad Sci U S A; 2018 Apr; 115(17):E3978-E3986. PubMed ID: 29632194
[TBL] [Abstract][Full Text] [Related]
13. RNA-binding protein KHSRP promotes tumor growth and metastasis in non-small cell lung cancer.
Yan M; Sun L; Li J; Yu H; Lin H; Yu T; Zhao F; Zhu M; Liu L; Geng Q; Kong H; Pan H; Yao M
J Exp Clin Cancer Res; 2019 Nov; 38(1):478. PubMed ID: 31775888
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of long intergenic noncoding RNA 00673 promotes tumor proliferation via LSD1 interaction and repression of NCALD in non-small-cell lung cancer.
Shi X; Ma C; Zhu Q; Yuan D; Sun M; Gu X; Wu G; Lv T; Song Y
Oncotarget; 2016 May; 7(18):25558-75. PubMed ID: 27027352
[TBL] [Abstract][Full Text] [Related]
15. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891
[TBL] [Abstract][Full Text] [Related]
16. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW
Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173
[TBL] [Abstract][Full Text] [Related]
17. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach.
Caiola E; Falcetta F; Giordano S; Marabese M; Garassino MC; Broggini M; Pastorelli R; Brunelli L
J Exp Clin Cancer Res; 2018 Dec; 37(1):302. PubMed ID: 30514331
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA LINC01133 represses KLF2, P21 and E-cadherin transcription through binding with EZH2, LSD1 in non small cell lung cancer.
Zang C; Nie FQ; Wang Q; Sun M; Li W; He J; Zhang M; Lu KH
Oncotarget; 2016 Mar; 7(10):11696-707. PubMed ID: 26840083
[TBL] [Abstract][Full Text] [Related]
20. INO80 is required for oncogenic transcription and tumor growth in non-small cell lung cancer.
Zhang S; Zhou B; Wang L; Li P; Bennett BD; Snyder R; Garantziotis S; Fargo DC; Cox AD; Chen L; Hu G
Oncogene; 2017 Mar; 36(10):1430-1439. PubMed ID: 27641337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
